GeoVax Labs, Inc. (GOVX)

NASDAQ: GOVX · IEX Real-Time Price · USD
1.960
+0.060 (3.16%)
Mar 28, 2024, 1:07 PM EDT - Market open

Company Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.

It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever.

GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute.

GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GeoVax Labs, Inc.
GeoVax Labs logo
Country United States
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 17
CEO David Alan Dodd

Contact Details

Address:
1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
United States
Phone 678-384-7220
Website geovax.com

Stock Details

Ticker Symbol GOVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000832489
CUSIP Number 373678507
ISIN Number US3736786068
Employer ID 87-0455038
SIC Code 2834

Key Executives

Name Position
David Alan Dodd Chairman, President and Chief Executive Officer
Dr. Mark J. Newman Ph.D. Chief Scientific Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Medical Officer
Dr. Harriet Latham Robinson Ph.D. Founder, Chief Scientific Officer Emeritus and Member of Scientific Advisory Board
Mark W. Reynolds CPA Chief Financial Officer and Corporate Secretary
Jeffrey Welch Head of Process Development and Manufacturing Operations
Dr. John W. Sharkey Ph.D. Vice President of Business Development

Latest SEC Filings

Date Type Title
Mar 13, 2024 EFFECT Notice of Effectiveness
Mar 11, 2024 10-K/A [Amend] Annual report
Mar 8, 2024 EFFECT Notice of Effectiveness
Mar 8, 2024 EFFECT Notice of Effectiveness
Mar 8, 2024 EFFECT Notice of Effectiveness
Mar 8, 2024 EFFECT Notice of Effectiveness
Mar 1, 2024 8-K Current Report
Mar 1, 2024 S-3 Registration statement under Securities Act of 1933
Mar 1, 2024 POS AM Post-Effective amendments for registration statement
Mar 1, 2024 POS AM Post-Effective amendments for registration statement